SCHEMBL416583

SCHEMBL416583

COc1cc(F)cc(-c2nc3c(Nc4ccc(-n5cnc(C)c5)c(OC)n4)cccc3n2C)c1

nearest known ligand 0.80

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 20/20 0.80
PSEN2 P49810 20/20 0.80
APH1B Q8WW43 20/20 0.80
NCSTN Q92542 20/20 0.80
APH1A Q96BI3 20/20 0.80
PSENEN Q9NZ42 20/20 0.80
KCNH2 Q12809 4/20 0.80
CYP3A4 P08684 1/20 0.80
CYP2D6 P10635 1/20 0.80
CYP2C9 P11712 1/20 0.80
CYP2C19 P33261 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL416555 0.95 PSEN1 (0.85) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL412719 0.94 PSEN1 (0.78) PSEN1PSEN2APH1BNCSTNAPH1A
Hydrochloric Acid SCHEMBL413725 0.93 PSEN1 (0.75) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL413769 0.91 PSEN1 (0.84) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL415053 0.90 PSEN1 (0.77) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL417100 0.90 PSEN1 (0.77) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL416113 0.90 PSEN1 (0.71) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL416639 0.89 PSEN1 (1.00) PSEN1PSEN2APH1BNCSTNAPH1A
Hydrochloric Acid SCHEMBL414566 0.88 PSEN1 (0.98) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL412711 0.88 PSEN1 (0.85) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8772504-B2 Substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives as gamma secretase modulators Janssen Pharmaceuticals, Inc. (US) 2014-07-08 US disclosed
EP-2398793-B1 NOVEL SUBSTITUTED BENZOXAZOLE, BENZIMIDAZOLE, OXAZOLOPYRIDINE AND IMIDAZOPYRIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS JANSSEN PHARMACEUTICALS INC (US) 2013-12-18 EP disclosed
US-20120022090-A1 NOVEL SUBSTITUTED BENZOXAZOLE, BENZIMIDAZOLE, OXAZOLOPYRIDINE AND IMIDAZOPYRIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS CELLZOME LIMITED (GB) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022090-A1 NOVEL SUBSTITUTED BENZOXAZOLE, BENZIMIDAZOLE, OXAZOLOPYRIDINE AND IMIDAZOPYRIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS BACE1, BACE2, GSAP PSEN1 4/4885PSEN2 6/4885APH1B 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.